Preview this article 1 min Regeneron's $2 billion plan for its Saratoga County facility got a big boost recently. © 2025 ...

Earlier in December, Regeneron Pharmaceuticals reported encouraging Phase 1/2 data for its investigational multiple myeloma ...

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

It's full steam ahead for a new Regeneron facility in Saratoga Springs. The company has learned that Saratoga County's ...

Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.

Exposure to antibiotics during immune checkpoint inhibitor therapy may increase the risk for immune-related cutaneous adverse ...

Pfizer Inc., AstraZeneca Plc and other companies have struck deals with the Trump administration in recent months ...

Merck's oral PCSK inhibitor for cholesterol, enlicitide, and its cancer antibody-drug conjugate sacituzumab tirumotecan ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a ...

In this video, Carolyn K. Pan, MD, a clinical professor of ophthalmology at Stanford University, discussed highlights in wet ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | On ...